Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus.
We present a live-attenuated RNA hybrid vaccine technology that uses an RNA vaccine delivery vehicle to deliver in vitro-transcribed, full-length, live-attenuated viral genomes to the site of vaccination. This technology allows ready manufacturing in a cell-free environment, regardless of viral attenuation level, and it promises to avoid many safety and manufacturing challenges of traditional live-attenuated vaccines. We demonstrate this technology through development and testing of a live-attenuated RNA hybrid vaccine against Chikungunya virus (CHIKV), comprised of an in vitro-transcribed, highly attenuated CHIKV genome delivered by a highly stable nanostructured lipid carrier (NLC) formulation as an intramuscular injection. We demonstrate that single-dose immunization of immunocompetent C57BL/6 mice results in induction of high CHIKV-neutralizing antibody titers and protection against mortality and footpad swelling after lethal CHIKV challenge.
['Voigt|Emily A|EA|', 'Fuerte-Stone|Jasmine|J|', 'Granger|Brian|B|', 'Archer|Jacob|J|', 'Van Hoeven|Neal|N|']
live-attenuated hybrid vaccine Chikungunya virus RNA vaccine nanostructured lipid carrier arthritis infection viral vaccine